CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.

Del Medical Imaging

Del Medical Imaging Corp. is a Roselle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Waterjel Technologies

Waterjel Technologies LLC is a Carlstadt, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Informatics Engineering

Founded in 1995, MIE has developed the WebChart EHR portfolio, a minimally invasive EHR which operates on any web browser or mobile device, including iPads or Smartphones.

Siren

Siren`s first commercial product is an FDA-registered temperature monitoring sock that connects wirelessly to a software application, allowing podiatrists to detect early signs of inflammation in patients at risk of developing diabetic foot ulcers.